|
 |
AggrastatThis page contains recent news articles, when available, and an overview of Aggrastat but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Aggrastat (when available) Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy. For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. Mechanism Of Action: Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of Tirofiban. News Articles on Tirofiban Medicure Announces Further Agreement With Secured Lender - Dec 22, 2009 The Company's primary business activity is the marketing and distribution of AGGRASTAT(R) (tirofiban hydrochloride) in the United States for acute coronary ... FOXBusiness New Management Hires for Burnham Aimed at Accelerating Commercialization Efforts - Oct 22, 2009 Burnham's pipeline includes three drugs that have already won FDA approval — heart attack medicines Integrilin and Aggrastat, and the cancer drug Targretin. ... GenomeWeb Daily News Medicure Appoints Eric Johnstone As CFO - Quick Facts - Nov 2, 2009 ...(RTTNews) - Medicure Inc. (MPH.TO: News ) announced the appointment of Eric Johnstone as Chief Financial Officer of the Company effective November 1. ... RTT News Merck Announces Third-Quarter 2009 Financial Results - Oct 22, 2009 ...a $300 million expense for a contribution to The Merck Company Foundation, a $249 million gain on the company's remaining worldwide rights to AGGRASTAT, ... Reuters Brand Names/Synonyms: Aggrastat is also known by the following brand names and/or synonymsAGG; Aggrastat; Tirofiban; Tirofiban [Ban:Inn] Drug Category: Aggrastat is categorized under the following by the FDA: Fibrinolytic Agents; Platelet Aggregation Inhibitors; ATC:B01AC17 Dosage Forms: LIQUID; SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 2-butylsulfonylamino-3-[4-[4-(4-piperidyl)butoxy]phenyl]-propanoic acid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
